logo-loader
viewAntisense Therapeutics Ltd

Full interview: Antisense Therapeutics further develops therapeutic for Duchenne Muscular Dystrophy with ATL1102

Antisense Therapeutics Limited (ASX:ANP) managing director Mark Diamond updates Proactive on the company’s progress in developing a therapeutic for a severe disease called Duchenne Muscular Dystrophy, or DMD.

The managing director spoke about the importance of the drug ATL1102 that is being progressed through the company’s Phase 2 trial, saying it has shown significant success.

Diamond says some important regulatory interactions necessary for efficient and timely advancement to the next stage of development of ATL1102 are underway.

Quick facts: Antisense Therapeutics Ltd

Price: 0.084 AUD

ASX:ANP
Market: ASX
Market Cap: $41.06 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Antisense Therapeutics Ltd named herein, including the promotion by the Company of Antisense Therapeutics Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Electric vehicle sales to accelerate following coronavirus pandemic

Roskill analyst Jose Lazuen tells Proactive London's Andrew Scott severe falls were expected in EV sales but that European and Chinese policies coupled with consumer preferences have shown them to remain strong. He adds that policy is going to favour and push EV sales in certain jurisdictions...

1 day, 16 hours ago

2 min read